

**In the Specification:**

Please replace paragraph [076] beginning at page 22, line 9, with the following:

A1  
--[076] Samples of the fractions having the highest inhibiting activity to soy bean inhibitor are further analysed by Western blot with anti SGT serum derived from guinea pigs (Fig. 3). The purity of the SGT is determined by analytical Reversed Phase HPLC, wherein purified SGT is loaded onto a reverse phase column (Nucleosil 300-5C18-150 x 2 mm) and eluted with a linear gradient of acetonitril. The chromatogram of the reversed HPLC is given in Fig. 4. Purity is expressed as relation of the main peak to the total peak area. The Reversed Phase HPLC of purified SGT demonstrates a purity of > 95%. The chromatogram shows a sharp peak which corresponds to SGT. Online HPLC-electroscopy ionisation mass spectroscopy (ESI-MS) is used to determine the molecular weight of purified SGT. As such, the major peak of the chromatogram has a molecular weight of 23096.5 D, which is in excellent agreement with the theoretical mas of 23099 D. The data is further corroborated by the assessment of the correct N-terminus (NH<sub>2</sub>-V-V-G-G-T-R-A-A-Q-G-E-F-P-F-M-V-) (SEQ ID NO:1).--

Please insert the accompanying paper copy of the Sequence Listing, page number 1, at the end of the application.

**REMARKS**


Applicants request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is accompanied by a floppy disk containing the above named sequence, SEQ ID NO:1, in computer readable form, and a paper copy of the sequence information which has been printed from the floppy disk.

The information contained in the computer readable disk was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy. This amendment contains no new matter.

Attached hereto is a marked-up version of the changes made to the Specification by the current Amendment. The attached pages are captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Kevin L. Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
KLB:dmw

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

Paragraph [076] beginning at line 7 of page 7 has been amended as follows:

[076] Samples of the fractions having the highest inhibiting activity to soy bean inhibitor are further analysed by Western blot with anti SGT serum derived from guinea pigs (Fig. 3). The purity of the SGT is determined by analytical Reversed Phase HPLC, wherein purified SGT is loaded onto a reverse phase column (Nucleosil 300-5C18-150 x 2 mm) and eluted with a linear gradient of acetonitril. The chromatogram of the reversed HPLC is given in Fig. 4. Purity is expressed as relation of the main peak to the total peak area. The Reversed Phase HPLC of purified SGT demonstrates a purity of > 95%. The chromatogram shows a sharp peak which corresponds to SGT. Online HPLC-electroscopy ionisation mass spectroscopy (ESI-MS) is used to determine the molecular weight of purified SGT. As such, the major peak of the chromatogram has a molecular weight of 23096.5 D, which is in excellent agreement with the theoretical mas of 23099 D. The data is further corroborated by the assessment of the correct N-terminus (NH<sub>2</sub>-V-V-G-G-T-R-A-A-Q-G-E-F-P-F-M-V-)(SEQ ID NO:1).



UNITED STATES PATENT AND TRADEMARK OFFICE



COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

**ATTACHMENT TO "NOTICE TO COMPLY WITH  
REQUIREMENTS...SEQUENCE DISCLOSURES"**

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be submitted using one of the following methods:

1. Electronically submitted through EFS-Bio  
(<http://www.uspto.gov/ebs/efs/downloads/documents.htm>, EFS Submission User Manual - ePAVE)
2. Mailed to:  
U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202
3. Mailed by Federal Express, United Parcel Service or other delivery service to:  
U. S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, Box Sequence  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, Virginia 22202
4. Hand Carried directly to the Customer Window at:  
2011 South Clark Place  
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,  
Arlington, Virginia 22202



#3

SEQUENCE LISTING

<110> Mitterer, Artur  
Tauer, Christa  
Reiter, Manfred  
Mundt, Wolfgang  
Baxter Vaccine AG

<120> Method of Isolation and Purification of Trypsin from  
Pronase and Use Thereof

<130> 20695C-002100US

<140> US 10/006,223

<141> 2001-12-10

<160> 1

<170> PatentIn Ver. 2.1

<210> 1

<211> 16

<212> PRT

<213> Streptomyces griseus

<220>

<221> PEPTIDE

<222> (1)..(16)

<223> Streptomyces griseus trypsin (SGT) N-terminus

<400> 1

Val	Val	Gly	Gly	Thr	Arg	Ala	Ala	Gln	Gly	Glu	Phe	Pro	Phe	Met	Val
1				5				10						15	